Topics

5 updates from Teva's busy quarter: A new CFO, a biosimilar launch and a migraine miss

06:51 EST 7 Nov 2019 | BioPharmaDive

Teva's stock went in an unfamiliar direction Thursday — up — as the pharma slightly beat Wall Street sales expectations with its quarterly results.

Original Article: 5 updates from Teva's busy quarter: A new CFO, a biosimilar launch and a migraine miss

NEXT ARTICLE

More From BioPortfolio on "5 updates from Teva's busy quarter: A new CFO, a biosimilar launch and a migraine miss"

Quick Search

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...